Elamin, A., Fadlallah, M., & Tuevmo, T
The competitive landscape changes are reflective of these companies' strategic alliances, licensing agreements, and targeted M&A to quickly gain access to the pipeline and enter the market
10.1001/jamainternmed.2024.4369 Summary Keywords cardiovascular disease, cardiovascular outcome, glucagon-like peptide-1 receptor agonists, heart failure, obesity Citation Turkistani Y (2025) Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Fras JP, Davies MJ, Rosenstock J, Prez Manghi FC, Fernndez Land L, Bergman BK, et al
They will likely adjust your preoperative fasting protocol, use specific intubation techniques, and may position you to reduce aspiration risk
See how it works, who can tak